Dr. Rahma Warsame (@RWarsameMD) sits down with Dr. Margo Rollins to explore the critical clinical importance of diverse blood donors and unique challenges faced in recruiting and retaining a diverse donor pool. They then delve into practical strategies and opportunities to overcome these barriers. Join us to gain valuable insights into how enhancing donor diversity can significantly improve patient outcomes and promote health equity.

Learning Objectives: To educate hematologists on…

1. The importance of donor diversity in blood donations.
2. Challenges faced in recruiting and retaining a diverse pool particularly from BIPOC communities.
3. Strategies toward overcoming these barriers.

Are you a healthcare professional seeking clarity on the evolving treatments for sickle cell disease (SCD)? 

In this 20-minute episode, experts from cellular therapy and bone marrow transplantation (BMT) explore key updates in SCD care, including curative therapies, gene-editing innovations, and BMT approaches. They address practical challenges in integrating these treatments into practice and discuss strategies to improve access and outcomes. Tune in to discover how collaboration between cellular therapy and BMT providers is transforming care and paving the way for better patient experiences. 

Learning Objectives 

1. Understand recent advancements in curative therapies, including gene editing and BMT, for sickle cell disease. 
2. Identify key challenges and barriers to integrating new treatments into clinical practice for SCD patients. 
3. Explore collaborative care strategies between cellular therapy and BMT providers to improve patient outcomes and access. 

Join us for an insightful podcast episode featuring the Co-Chairs of the upcoming 2024 ASH Annual Meeting, where we explore the planning process and strategic goals that shaped this year’s program. Discover how the Co-Chairs ensured the Education Program meets the diverse needs of the hematology community, and the unique challenges faced during the planning and how they were overcome. Gain exclusive insights into what makes this event the premier gathering for professionals in the field. Whether attending in person or virtually, find out how you can maximize your experience and apply the latest advancements to your practice or research.

Learning Objectives:

1. Understand the Planning Process: Learn about the strategic goals, collaborative efforts, and decision-making that guided the design of the Education Program for the 66th ASH Annual Meeting, ensuring it addresses the diverse needs of the hematology community.
2. Overcome Planning Challenges: Learn about the specific challenges encountered during the planning of this year’s program and how they were effectively managed to deliver a meaningful experience for attendees.
3. Impact on Practice and Research: Understand how this year’s program is designed to impact attendees' practices and research, fostering advancements in the field of hematology.

Join us as we explore blood transfusion safety, focusing specifically on Transfusion-Related Acute Lung Injury (TRALI) and Transfusion-Associated Circulatory Overload (TACO). Tailored for general hematologists with a foundational understanding of transfusion medicine, this session delves into the pathophysiology, clinical presentation, diagnostic criteria, and management strategies for TRALI and TACO. Through advanced discussions, participants will deepen their knowledge of these complications, enabling them to recognize, diagnose, and manage TRALI and TACO effectively in clinical practice.

Learning Objectives:

1. Gain a thorough understanding of the pathophysiology and clinical presentation of TRALI and TACO.
2. Familiarize with the diagnostic criteria and differential diagnosis of TRALI and TACO.
3. Develop effective management strategies for TRALI and TACO to ensure transfusion safety and enhance patient outcomes.

Are you a hematologist or a generalist provider seeking clarity on how to best counsel patients with sickle cell disease (SCD) who are interested in gene therapy? Join us for a podcast session focused on important patient considerations for gene therapy, tailored for SCD providers and clinicians. This session aims to provide practical insights to facilitate clear communication between providers, patients with SCD, and their families about treatment options.

Learning Objectives

1. Understand the Basics of Gene Therapy Treatments & SCD: By the end of the podcast, listeners will be able to identify some basic tenants of transformative treatments for sickle cell disease (SCD), focusing on how gene therapy treatments compare to other disease modifying treatments.
2. Counseling Patients and Families: Listeners will be given suggestions on what key information to provide to patients and families that are interested in gene therapies, especially considering the build-up to gene therapy and also potential long-term effects.
3. Enhance Communication Skills: This episode will suggest effective communication strategies to provide patients with both perspective and empathy while discussing gene therapy and other treatment options.

Speakers: Alexis Thompson, MD, and Sujit Sheth, MD

Description:

For general hematologists with a foundational understanding of thalassemia, this episode discusses the changing demographics due to immigration and refugee resettlement. It covers the diagnosis process from newborn screening to older individuals, emphasizing genetic testing due to numerous mutations and varied phenotypes. The importance of correctly diagnosing older individuals previously misdiagnosed with iron deficiency refractory to treatment is highlighted. The episode also addresses regular transfusions, iron chelation, and monitoring for complications, along with advances in blood supply safety, reduced alloimmunization risks through extended typing, and MRI monitoring. Finally, novel agents in practice and development, including luspatercept, PK activators, and gene therapy, will be explored.
 

Learning Objectives:

1. Understand the changing landscape of thalassemia in the US. 
2. Revisit the state-of-the-art diagnostic and treatment approaches. 
3. Learn about novel therapeutics in the thalassemia field.

Dr. Azam Farooqui (@azamfarooqui ) and Dr. Monique Hartley-Brown (@DrMHB1) discuss therapeutic considerations regarding current and emerging agents for patients with multiple myeloma from underrepresented racial and ethnic groups.

Coming Soon!

Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will develop an increased ability to identify variations in factors influencing mortality and survival outcomes among individuals from racial and ethnic minority groups with multiple myeloma.

Music: “Happy Medium” Zac Nelson (shutterstock.com). Licensed under Shutterstock: Standard License.

Dr. Azam Farooqui (@azamfarooqui )and Dr. Sikander Ailawadhi answer the question: Why do we need earlier diagnosis and intervention in patients with multiple myeloma from underrepresented racial and ethnic groups?

Coming Soon!

Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will develop an increased ability to identify variations in factors influencing mortality and survival outcomes among individuals from racial and ethnic minority groups with multiple myeloma.

Music: “Happy Medium” Zac Nelson (shutterstock.com). Licensed under Shutterstock: Standard License.

Dr. Azam Farooqui (@azamfarooqui) and Dr. Urvi Shah (@UrviShahMD) identify factors that impact outcomes for patients with multiple myeloma from underrepresented racial and ethnic groups.

Coming Soon!

Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will develop an increased ability to identify variations in factors influencing mortality and survival outcomes among individuals from racial and ethnic minority groups with multiple myeloma.

Music: “Happy Medium” Zac Nelson (shutterstock.com). Licensed under Shutterstock: Standard License.

Season 2: IMPACT II: Impacting Multiple Myeloma in All CommuniTies

Unlock insights into the treatment of multiple myeloma within underrepresented racial and ethnic populations with this series of three enlightening podcast episodes. Join experts from both academic and community oncology settings as they dive into critical aspects of clinical risk, survival outcomes, and treatment considerations.

Episode 1: Uncover the factors influencing outcomes for multiple myeloma patients from underrepresented racial and ethnic groups with Dr. Shah.

Episode 2: Join Dr. Ailawadhi in exploring a hypothetical scenario of equal conditions and envision how mortality and survival outcomes may differ for multiple myeloma patients from underrepresented groups. 

Episode 3: Gain valuable insights from Dr. Hartley-Brown as she discusses therapeutic considerations for both current and emerging agents tailored to multiple myeloma patients from underrepresented racial and ethnic backgrounds.

Are you ready to expand your understanding of multiple myeloma treatment disparities? Listen to Season 2 of HemeTalks on Apple Podcasts, Spotify, Google Podcasts, or your preferred podcast platform! Don't forget to bookmark the ASH Podcast webpage for easy access.

Coming Soon ASH Academy On Demand!

Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will develop an increased ability to identify variations in factors influencing mortality and survival outcomes among individuals from racial and ethnic minority groups with multiple myeloma.

Music: "PeriTune - Investigation2(Suspense-Royalty Free Music)" by PeriTune is licensed under CC BY 3.0.